Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
ZURA · against 403 other Healthcare companies of similar size
Ranked #253 of 404 · scores higher than 11% of peers
Bars: peers in each 10-point band of the valuation score152 peers with a valuation score of 0–9, including ZURA · Click a bar to see the companies
Mainly because of its EBITDA yield, earnings yield and free cash flow yield, which are weaker than most Healthcare peers.
| Metric | ZURA | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 390 reported | -27.8% | -0.0% | 13% | 30% | |
| EBITDA yieldHigher is better · 409 reported | -52.3% | 2.8% | 7% | 50% | |
| Free cash flow yieldHigher is better · 192 reported | -20.3% | -8.5% | 26% | 20% | |
| Book yieldHigher is better · 401 reported | 51.8% | 49.3% | 52% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 3.5B HKD (≈$451M) | 99 | 51 | |
| 1 | 2.9B HKD (≈$365M) | 99 | 84 | |
| 1 | 89.9B JPY (≈$611M) | 99 | 68 | |
| 1 | 3.1B HKD (≈$396M) | 99 | 61 | |
| 1 | 29.0B JPY (≈$197M) | 99 | 56 | |
| 253 | 227M USD | 8 | 24 | |
| 253 | 595M USD | 8 | 29 | |
| 253 | 705M USD | 8 | 32 | |
| 253 | 453M USD | 8 | 6 | |
| 253 | 382M USD | 8 | ||
| 360 | 1.9B CNY (≈$270M) | 7 | 17 | |
| 360 | 3.3B CNY (≈$458M) | 7 | 49 | |
| 360 | 4.1B CNY (≈$575M) | 7 | 34 | |
| 360 | 3.3B CNY (≈$463M) | 7 | 26 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score